1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung & Blood Vessel Diseases, Beijing, China.
Int Rev Immunol. 2014 Jan;33(1):34-44. doi: 10.3109/08830185.2013.816699. Epub 2013 Aug 5.
Recent studies have suggested that interleukin (IL)-18 gene (-137G/C) polymorphism is associated with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). However, other studies did not confirm this correlation.
The objective of this study was to evaluate the relationships of IL-18 -137G/C and RA and SLE using a meta-analysis.
Pubmed, Embase and Cochrane library databases were systemically searched. Data were extracted by two independent reviewers and pooled odds ratio (OR) with 95% confidence interval (CI) was calculated.
In RA, the overall ORs and 95% CIs of -137C were 1.03, 0.88-1.22 (p=0.391); 1.22, 0.89-1.68 (p=0.020) and 1.06, 0.93-1.21 (p=0.110) in dominant, recessive, and additive models, respectively. Furthermore, in SLE, the overall ORs and 95% CIs of -137C were 1.10, 0.94-1.29 (p=0.980); 1.21, 0.91-1.60 (p=0.010) and 1.10, 0.97-1.24 (p=0.454) in dominant, recessive, and additive models, respectively. IL-18 -137G/C could increase the risk of RA and SLE. No publication bias was found in this meta-analysis. After population stratification analysis, under recessive model, the pooled ORs and 95% CIs of -137C were 1.14, 0.82-1.60 (p=0.008) and 1.01, 0.66-1.55 (p=0.004) in European RA patients and Asian SLE patients, respectively.
This meta-analysis showed that IL-18 -137G/C was a risk factor for RA and SLE, especially for RA in Europeans and SLE in Asians.
最近的研究表明，白细胞介素（IL）-18 基因（-137G/C）多态性与类风湿关节炎（RA）和系统性红斑狼疮（SLE）有关。然而，其他研究并未证实这种相关性。
本研究旨在通过荟萃分析评估 IL-18-137G/C 与 RA 和 SLE 的关系。
系统检索 Pubmed、Embase 和 Cochrane 图书馆数据库。由两名独立评审员提取数据，并计算合并优势比（OR）及其 95%置信区间（CI）。
在 RA 中，-137C 的总体 OR 和 95%CI 为 1.03、0.88-1.22（p=0.391）；1.22、0.89-1.68（p=0.020）和 1.06、0.93-1.21（p=0.110），分别为显性、隐性和加性模型。此外，在 SLE 中，-137C 的总体 OR 和 95%CI 为 1.10、0.94-1.29（p=0.980）；1.21、0.91-1.60（p=0.010）和 1.10、0.97-1.24（p=0.454），分别为显性、隐性和加性模型。IL-18-137C 可能会增加 RA 和 SLE 的风险。本荟萃分析未发现发表偏倚。经过人群分层分析，在隐性模型下，-137C 的合并 OR 和 95%CI 在欧洲 RA 患者和亚洲 SLE 患者中分别为 1.14、0.82-1.60（p=0.008）和 1.01、0.66-1.55（p=0.004）。
本荟萃分析表明，IL-18-137G/C 是 RA 和 SLE 的危险因素，特别是对欧洲 RA 和亚洲 SLE 而言。
